Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth

BACKGROUND: The most common genetic changes identified in human NSCLC are Kras mutations (10–30 %) and p53 mutation or loss (50–70 %). Moreover, NSCLC with mutations in Kras and p53 poorly respond to current therapies, so we are trying to find a new target for the treatment strategies. METHODS: Flow...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Huanan, Wang, Lei, Zhang, Yingjie, Wang, Ji, Deng, Yibin, Lin, Degui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Primary Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755025/
https://www.ncbi.nlm.nih.gov/pubmed/26884725
http://dx.doi.org/10.1186/s12935-016-0280-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755025/
https://www.ncbi.nlm.nih.gov/pubmed/26884725
http://dx.doi.org/10.1186/s12935-016-0280-y

Ejemplares similares